evodiamine has been researched along with Disease Models, Animal in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 9 (64.29) | 24.3611 |
| 2020's | 4 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
| Chen, YD; Han, B; Li, P; Liao, QF; Lin, L; Lin, YX; Tian, X; Wang, MX; Xie, ZY; Zhong, YP | 1 |
| Cui, Y; Wang, J; Wang, Q; Wu, X | 1 |
| Chou, CH; Yang, CR | 1 |
| Luo, HS; Ren, HX; Tang, QC; Xia, H; Yan, L | 1 |
| Chen, Y; Wu, P | 1 |
| Cai, G; Cai, J; Gao, R; Ji, Q; Li, C; Li, Q; Song, D; Sui, H; Teng, P; Wang, Y; Zhou, L | 1 |
| Gao, X; Guo, Q; Han, Y; Hu, C; Liu, M; Wang, J; Wang, Y; Zhang, K | 1 |
| Tan, Q; Zhang, J | 1 |
| Gao, K; Liu, JN; Ma, CM; Qin, C; Quan, XZ; Wang, DM; Yuan, SM; Zhang, LF | 1 |
| Cheng, LC; Ching, LC; Kou, YR; Lee, TS; Pan, CC; Shyue, SK; Su, KH; Wei, J; Yu, YB | 1 |
| Chen, F; Ding, JS; Li, D; Li, S | 1 |
| Ching, LC; Kou, YR; Lee, HF; Lee, TS; Shyue, SK; Wei, J; Zhao, JF | 1 |
| Bae, EA; Cai, XF; Kim, DH; Lee, JJ; Shin, YW | 1 |
1 review(s) available for evodiamine and Disease Models, Animal
| Article | Year |
|---|---|
Evodiamine and Its Role in Chronic Diseases.
Topics: Analgesics; Animals; Anti-Allergic Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Obesity Agents; Antineoplastic Agents, Phytogenic; Chronic Disease; Disease Models, Animal; Evodia; Humans; Molecular Structure; Phytotherapy; Plants, Medicinal; Quinazolines; Signal Transduction; Structure-Activity Relationship | 2016 |
13 other study(ies) available for evodiamine and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
Evodiamine has therapeutic efficacy in ulcerative colitis by increasing Lactobacillus acidophilus levels and acetate production.
Topics: Acetates; Animals; Colitis, Ulcerative; Colon; Cytokines; Dextran Sulfate; Disease Models, Animal; Fecal Microbiota Transplantation; Feces; Gastrointestinal Agents; Gastrointestinal Microbiome; Inflammation Mediators; Intestinal Mucosa; Lactobacillus acidophilus; Male; Metabolomics; Quinazolines; Rats, Sprague-Dawley; Ribotyping | 2020 |
Evodiamine protects against airway remodelling and inflammation in asthmatic rats by modulating the HMGB1/NF-κB/TLR-4 signalling pathway.
Topics: Airway Remodeling; Animals; Anti-Inflammatory Agents; Asthma; Bronchoalveolar Lavage Fluid; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Evodia; HMGB1 Protein; Inflammation; NF-kappa B; Quinazolines; Rats; Rats, Sprague-Dawley; Signal Transduction; Toll-Like Receptor 4 | 2021 |
Neuroprotective Studies of Evodiamine in an Okadaic Acid-Induced Neurotoxicity.
Topics: Alzheimer Disease; Animals; Apoptosis; Brain; Cell Line; Cognition; Cognition Disorders; Disease Models, Animal; Humans; Male; Maze Learning; Mice; Mice, Inbred ICR; Neurodegenerative Diseases; Neurons; Neuroprotection; Neuroprotective Agents; Okadaic Acid; Phosphorylation; Quinazolines; Spatial Memory; tau Proteins; Tauopathies | 2021 |
Evodiamine inhibits gastrointestinal motility via CCK and CCK1 receptor in water-avoidence stress rat model.
Topics: Animals; Avoidance Learning; Biomarkers; Disease Models, Animal; Gastrointestinal Motility; Male; Quinazolines; Rats; Rats, Sprague-Dawley; Receptors, Cholecystokinin; Sincalide; Stress, Psychological | 2018 |
Evodiamine ameliorates paclitaxel-induced neuropathic pain by inhibiting inflammation and maintaining mitochondrial anti-oxidant functions.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cytokines; Disease Models, Animal; Ganglia, Spinal; Humans; Inflammation Mediators; Male; Membrane Potential, Mitochondrial; Mitochondria; Neuralgia; Oxidative Stress; Paclitaxel; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Phytotherapy; Quinazolines; Rats, Sprague-Dawley; Superoxide Dismutase; Tumor Cells, Cultured; Uncoupling Protein 2 | 2019 |
Development of EGFR-targeted evodiamine nanoparticles for the treatment of colorectal cancer.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Male; Mice; Mice, Inbred ICR; Molecular Structure; Neoplasms, Experimental; Quinazolines; Structure-Activity Relationship; Tumor Cells, Cultured | 2019 |
Evodiamine sensitizes BGC-823 gastric cancer cells to radiotherapy in vitro and in vivo.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Humans; Immunohistochemistry; Male; Mice; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Radiation-Sensitizing Agents; Receptor, ErbB-2; Stomach Neoplasms; Xenograft Model Antitumor Assays | 2016 |
Evodiamine improves congnitive abilities in SAMP8 and APP(swe)/PS1(ΔE9) transgenic mouse models of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Cognition; Disease Models, Animal; Maze Learning; Memory; Mice; Mice, Transgenic; Presenilin-1; Quinazolines; Random Allocation | 2011 |
Molecular mechanisms of activation of endothelial nitric oxide synthase mediated by transient receptor potential vanilloid type 1.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Capsaicin; Cattle; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelial Cells; Enzyme Activation; Humans; Mice; Mice, Inbred C57BL; Mice, Knockout; Nitric Oxide; Nitric Oxide Synthase Type III; Phosphatidylinositol 3-Kinase; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; RNA Interference; Signal Transduction; Time Factors; Transfection; TRPV Cation Channels | 2011 |
Transdermal behaviors comparisons among Evodia rutaecarpa extracts with different purity of evodiamine and rutaecarpine and the effect of topical formulation in vivo.
Topics: Administration, Cutaneous; Analgesics; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Evodia; Female; Indole Alkaloids; Male; Mice; Oleic Acid; Pain; Plant Extracts; Quinazolines; Sesquiterpenes; Skin; Swine | 2012 |
Essential role of transient receptor potential vanilloid type 1 in evodiamine-mediated protection against atherosclerosis.
Topics: Animals; Apolipoproteins E; Blotting, Western; Coronary Artery Disease; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Fatty Liver; Hyperlipidemias; Male; Mice; Mice, Knockout; Quinazolines; TRPV Cation Channels | 2013 |
In vitro and in vivo antiallergic effect of the fructus of Evodia rutaecarpa and its constituents.
Topics: Alkaloids; Animals; Anti-Allergic Agents; Behavior, Animal; Cell Degranulation; Cell Line, Tumor; Disease Models, Animal; Dose-Response Relationship, Drug; Evodia; Fruit; Indole Alkaloids; Interleukin-4; Male; Mast Cells; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; p-Methoxy-N-methylphenethylamine; Passive Cutaneous Anaphylaxis; Plant Extracts; Pruritus; Quinazolines; Rats; Rats, Sprague-Dawley; Tumor Necrosis Factor-alpha | 2007 |